Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Scientific Enters into a Long-Term Agreement with Fujirebio

Published: Thursday, November 22, 2012
Last Updated: Wednesday, November 21, 2012
Bookmark and Share
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.

Thermo Fisher Scientific Inc. has announced that it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse™ family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

The agreement focuses on Japan, where Fujirebio’s Lumipulse product line is placed in a significant number of hospitals and clinical reference labs and will be extended with future placements of Lumipulse platforms in other markets worldwide.

The PCT assay is available worldwide on several different laboratory instruments from strategic license partners.

In Europe, the PCT test, which has been the gold standard for the early detection of sepsis in critically ill patients, helps doctors to make an early determination whether an infection is bacterial or viral and quickly provides information on the severity of a patient’s condition for appropriate treatment and therapy monitoring.

In Japan, the PCT assay is used in patients suspected of having sepsis. Broader availability of PCT testing for diagnosing sepsis will lead to improved hospital management.

“This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patient’s outcome,” said Marc Tremblay, president of Thermo Fisher Scientific’s Clinical Diagnostics business.

Tremblay continued, “Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost-savings.”

Sepsis causes more deaths per year than prostate cancer, breast cancer and HIV/AIDS combined and claims 10,000 lives worldwide every day.

Prevalence has increased dramatically over the last decade, increasing in the developed world by 8 to 13 percent annually, making it one of the most pressing healthcare challenges faced by the world.

Severe sepsis strikes more than 750,000 Americans each year, and between 28 and 50 percent patients affected die within the first month of diagnosis.

Hospital costs to treat severe sepsis in the U.S. are estimated at $16 billion dollars annually.

Much of this cost is attributed to misdiagnosis or delayed diagnosis, making rapid, more reliable detection a national, if not global, imperative.

Research published in the journal Critical Care Medicine showed that each hour of delay in therapy can decrease chances of patient survival by 7.6 percent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher, Cytonome/ST Announce Partnership
Partnership aims to focus on the development of a new line of flow cytometry cell sorting platforms.
Tuesday, June 28, 2016
Thermo, Children’s Hospital Los Angeles Partner
Children’s Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA’s first NGS panel designed to target biomarkers associated with childhood cancers.
Friday, February 19, 2016
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.
Monday, June 02, 2014
Thermo Fisher Scientific Announces 4th Annual Cellome Award Winner
Vishal Deshmukh, Scripps Institute to accept award for excellence in the application of high content technology in Multiple Sclerosis research.
Wednesday, February 26, 2014
Thermo Reports 6% Q4 Revenue Growth
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.
Friday, January 31, 2014
One Lambda Receives CE Mark Approval for C1qScreen
Assay cited in New England Journal of Medicine for use in determining impact on kidney graft survival.
Tuesday, November 19, 2013
Thermo Scientific Selected to Supply Maybridge Fragment Library for Key Research
Recommended for use by renowned fragment library design expert.
Tuesday, February 05, 2013
Record Revenues for Thermo Fisher Scientific
Revenue for the quarter grew 6% to $3.26 billion in 2012, versus $3.09 billion in 2011.
Thursday, January 31, 2013
Thermo Fisher Scientific Announces Application Deadlines for Life Sciences Scholarships
Thermo Scientific Pierce Scholarship Winter/Spring semester applications due December 14, 2012.
Wednesday, November 14, 2012
Thermo Fisher Scientific Introduces Guide to Good Washing Practice
The online guide is designed to provide detailed guidance on obtaining secure and reliable performance with every use of the Thermo Scientific Wellwash microplate washers.
Thursday, October 21, 2010
Thermo Fisher Scientific Launches Maybridge Ro3 Diversity Fragment Library
Diverse set of 1,500 molecules engineered for high-quality fragment screening-based programmes.
Tuesday, July 06, 2010
Thermo Fisher Scientific Names Recipients of RNAi Discovery Grants
More than $400,000 in RNAi screening tools awarded to advance biomedical research and drug discovery.
Friday, November 06, 2009
Thermo Fisher Scientific Signs Agreement to Acquire B.R.A.H.M.S. AG
Company acquires provider of specialty in-vitro diagnostic tests for $470 million USD.
Monday, September 07, 2009
Thermo Fisher Scientific to Showcase Innovative Mass Spectrometry Solutions at IMSC 2009
Company will showcase a variety of mass spectrometry software and hardware solutions to deliver improved analytical performance.
Monday, September 07, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!